Poster Abstract Session:
047. Clinical: Skin and Soft Tissue
Thursday, October 5, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD


Presentations:
251
Risk Factors for Pseudomonas aeruginosa in Diabetic Foot Infections
Nada Farhat, PharmD; Daniel McClung, MD; Jerod Nagel, PharmD, BCPS
252
Less Is More: Surgical Procedure Time and Risk of Infections, Length-of-Stay, and Readmission across Three Distinct Surgeries
Ronak Parikh, DO; Nirav Shah, MD, MPH; Huma Saeed, M.D.; Eric Bhaimia, D.O.; Frances Lahrman, DO; Moira C. McNulty, MD; Ari Robicsek, MD; Rema Padman, PhD; Jennifer Grant, MD
253
Microbiology and Clinical Characteristics of Industrial Oil Burns
Devin Kelly, DO; Julie Rizzo, MD; Heather Yun, MD, FIDSA; Dana Blyth, MD
254
Hospital Costs for Patients with Lower Extremity Cellulitis: A Retrospective Population-Based Study
Douglas Challener, MD; Jasmine R. Marcelin, MD; Sue Visscher, Ph.D.; Larry M. Baddour, MD
Posters
  • Challener_2017.pdf (1.1 MB)
  • 255
    Sex Work, Injection Drug Use, and Abscesses: Associations in Women, But Not Men
    Deirdre Burke, MPH; Alysse Wurcel, MD, MS; David Landy, BS; Margie Skeer, ScD, MPH, MSW; Robert Heimer, PhD; Kenneth K. H. Chui, PhD; Thomas Stopka, PhD, MHS
    Posters
  • IDWEEK_poster_9.22.2017.pdf (782.3 kB)
  • 256
    Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
    Benjamin Georgiades, PharmD; Urania Rappo, MD, MS, PharmD; Pedro L. Gonzalez, MD; Jennifer S. McGregor, RPh; Jie Chen, PhD; Matthew McCarthy, MD
    257
    More than just an Anti-Infective Agent: A Prospective Pilot Clinical Trial to Determine the Effectiveness of IV Ertapenem in Severe Hidradenitis Suppurativa
    Mayur Ramesh, MD; Rachna Jayaprakash, MD; Zachary Hanna, (DO); Kulothungan Gunasekaran, MD; Tricia Stein, MD; Odaliz Abreu-Lanfranco, MD
    258
    High Rates of Multidrug Resistance in Diabetic Foot Infection in Detroit Area: Does It Matter?
    Oryan Henig, MD; Jason M. Pogue, PharmD; Raymond Cha, PharmD; Sorabh Dhar, MD; Umar Hayat, MD; Mahmoud Ja'Ara, Student; Paul E Kilgore, MPH, MD; Keith S. Kaye, MD, MPH
    259
    Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    Michael J. Rybak, PharmD, MPH, PhD; Evan J. Zasowski, PharmD, MPH, BCPS; Trang D. Trinh, PharmD, MPH, BCPS, AAHIVP; Abdalhamid M. Lagnf, MPH; Vasileios Margaritis, DDS, MSc., Ph.D.; Aaron B. Mendelsohn, M.P.H., Ph.D.
    260
    Post-discharge antibiotic therapy in patients with acute bacterial skin and skin structure infections
    Aisling Caffrey, PhD, MS; Maya Beganovic, Pharm.D., MPH; Vrishali Lopes, MS; Kerry LaPlante, Pharm.D., FCCP, FIDSA
    Posters
  • IDweek_ARC_05Sep2017.pdf (1014.8 kB)
  • 263
    Orthopedic-implant associated infection due to Gram-negative bacilli: the worrisome impact of Acinetobacter baumannii multidrug resistance in a Brazilian center
    Raquel Silva, MD; Mauro Costa Salles, MD; Roberta Matosa, Nurse; Bernardo Ayres, MD; Viviane Dias, MD; Luciana M. Caetano, M.D.
    265
    Dynamics of S. aureus acquisition and colonization in a military training environment
    Carey Schlett, MPH; Eugene Millar, PhD; Emad Elassal, MS; Natasha Law, MA; Demond Lyles, CRA; Arile Hadley, BS; Sidney Dowlen, CRA; David Hardge, MBA; Michael Ellis, MD; Jason Bennett, MD, MSPH
    267
    Identification of Pathogens Directly From Diabetic Foot Infections by Shotgun Metagenomic Sequencing
    James Shurko, PharmD; Steven Dallas, PhD; Bryson M. Duhon, Pharm.D.; Jordan Meckel, PharmD; Chiou-Miin Wang, PhD; Chun-Lin Lin, PhD; Nicholas Lucio, B.S.; Nameer Kirma, PhD; Grace C. Lee, PharmD, PhD
    269
    Diabetic Foot Wounds: Which Patients are More Prone to Tetanus?
    Ferit Kuscu, MD; Behice Kurtaran, Associate Professor; Aslihan Ulu, Assistant professor; Mehtap Evran, Assistant Professor; Seza Inal, Assistant Professor; Suheyla Komur, Assistant Professor; Salih Cetiner, Associated Professor; Yesim Tasova, Professor; Hasan Salih Zeki Aksu, professor

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.